Radiotheranostics: A Paradigm Shift in Precision Oncology - Dr. Johannes Czernin

This presentation will focus on prospective clinical trials in prostate cancer that led to successful New Drug Applications (NDAs) by the US Food and Drug Administration, and resulted in inclusion in the NCCN prostate cancer guidelines and reimbursement by the US Medicare system as well as ongoing phase 3 clinical trials that will position theranostics earlier in the course of prostate cancer will be presented. Finally, experiences from the recently opened large UCLA theranostics outpatient center, the role and importance of inter-disciplinary collaborations, developments in industry and academia aimed at improving supply of and access to theranostics, and the overall business case will be highlighted.